$AVNR..Will report out topline Ph.2 data for AVP-923 for the treatment of agitation in Alzheimer's late Sep/early Oct. Then they have PDUFA date on Nov 26th for AVP-825 for the treatment of Acute Migraine.
ECYT-late breaking abstract presentation at ESMO on saturday FYI. This might be one to watch. Strong cash position. Share may get nice spike if anything positive comes out